194 related articles for article (PubMed ID: 20171036)
1. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.
Serruys PW; Onuma Y; Garg S; Vranckx P; De Bruyne B; Morice MC; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; Schuijer M; Rademaker T; Wittebols K; Stoll HP;
J Am Coll Cardiol; 2010 Mar; 55(11):1093-101. PubMed ID: 20171036
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
van Domburg RT; Daemen J; Morice MC; de Bruyne B; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; van Es GA; Wittebols K; Macours N; Stoll HP; Serruys PW
EuroIntervention; 2010 Apr; 5(8):962-7. PubMed ID: 20542782
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II).
Kukreja N; Serruys PW; De Bruyne B; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; Goedhart D; Macours N; Stoll HP;
Heart; 2009 Jul; 95(13):1061-6. PubMed ID: 19304671
[TBL] [Abstract][Full Text] [Related]
4. 5-Year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (arterial revascularization therapy study)-II and ARTS-I trials.
Onuma Y; Wykrzykowska JJ; Garg S; Vranckx P; Serruys PW;
JACC Cardiovasc Interv; 2011 Mar; 4(3):317-23. PubMed ID: 21435610
[TBL] [Abstract][Full Text] [Related]
5. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
Serruys PW; Daemen J; Morice MC; De Bruyne B; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; Dawkins KD; Vranckx P; Bressers M; van Domburg R; Schuijer M; Wittebols K; Pieters M; Stoll HP
EuroIntervention; 2008 Jan; 3(4):450-9. PubMed ID: 19736087
[TBL] [Abstract][Full Text] [Related]
7. Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study.
Garg S; Sarno G; Gutiérrez-Chico JL; Garcia-Garcia HM; Gomez-Lara J; Serruys PW;
EuroIntervention; 2011 Apr; 6(9):1060-7. PubMed ID: 21518677
[TBL] [Abstract][Full Text] [Related]
8. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
Daemen J; Kuck KH; Macaya C; LeGrand V; Vrolix M; Carrie D; Sheiban I; Suttorp MJ; Vranckx P; Rademaker T; Goedhart D; Schuijer M; Wittebols K; Macours N; Stoll HP; Serruys PW;
J Am Coll Cardiol; 2008 Dec; 52(24):1957-67. PubMed ID: 19055986
[TBL] [Abstract][Full Text] [Related]
9. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II.
Vaina S; Voudris V; Morice MC; De Bruyne B; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; Schuijer M; Macours N; Stoll HP; Cokkinos DV; Stefanadis C; Serruys PW;
EuroIntervention; 2009 Jan; 4(4):492-501. PubMed ID: 19284072
[TBL] [Abstract][Full Text] [Related]
10. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
[TBL] [Abstract][Full Text] [Related]
11. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
12. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
[TBL] [Abstract][Full Text] [Related]
13. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
[TBL] [Abstract][Full Text] [Related]
15. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
16. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
[TBL] [Abstract][Full Text] [Related]
17. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
Sinning JM; Baumgart D; Werner N; Klauss V; Baer FM; Hartmann F; Drexler H; Motz W; Klues H; Voelker W; Pfannebecker T; Stoll HP; Nickenig G;
Am Heart J; 2012 Mar; 163(3):446-53, 453.e1. PubMed ID: 22424016
[TBL] [Abstract][Full Text] [Related]
18. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
19. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.
Maeng M; Tilsted HH; Jensen LO; Kaltoft A; Kelbæk H; Abildgaard U; Villadsen AB; Krusell LR; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Madsen M; Thayssen P; Sørensen HT; Thuesen L; Lassen JF
JACC Cardiovasc Interv; 2012 Aug; 5(8):812-8. PubMed ID: 22917452
[TBL] [Abstract][Full Text] [Related]
20. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
